Interesting stuff, Jeanne
>X-Mailer: Mozilla 3.01 (Win95; I)
>Date: Mon, 22 Mar 1999 09:40:11 -0800
>Reply-To: housecat@wenet.net
>Sender: "ANGIOGEN: Current Research on Angiogenesis"
<ANGIOGEN@LISTSERV.ACOR.ORG>
>From: randy cervantes <housecat@wenet.net>
>Subject: [ANGIOGEN] Endostatin Info/Wisconsin
>X-To: bhaines@uswest.net
>X-cc: CLL@listserv.acor.org, ALL-L@LISTSERV.ACOR.ORG,
> nhl@jubjub.wizard.com, myeloma@listserv.acor.org
>To: ANGIOGEN@LISTSERV.ACOR.ORG
>
>All,
>Just got off the phone with Julie Fiers (cancer connect nurse) at the
>University of Wisconsin (Endostatin site). Here is some info about the
>upcomming Endostatin trials there:
>
>Principal Investigator: Dr. George Wilding
>
>The clinical protocol has not yet been written for Endostatin. The
>University has to write this, send it to the NCI, then the NCI sends it
>back. This has something to do with the 6 months waiting period we keep
>hearing about.
>
>Entremed is still doing some stability testing on Endostatin before they
>are ready to release it.
>
>Some Eligibility requirments:
>*No brain metastasis
>*Patient must be able to be 'up and around' and take care of themselves
>(example: light housework, etc)
>*Patient has to have 'ordinary' lab tests results (example: kidney &
>bone marrow ordinary with some fluctuation allowed)
>*Patients will do multiple scans (pet, ct, mri, etc) to monitor response
>to drug.
>*Extensive time commitment for patients in trial required.
>*Repeated biopsy's of tumor sites required.
>
>Note: When I asked Julie if someone could possible get in under
>compassionate use/single use investigational new drug, she said she
>doubted that would be possilbe at phase 1 trial point.
>
>Randy Cervantes
>P.S. I keep hearing a small and fast phase 1 trial, with a much larger
>phase two trial to follow. It is no longer a dream, folks,
>Endostatin is ramping up and preparing.
> It is going to happen! And soon! Hope is alive!
>
>
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
